These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29631850)

  • 1. Delayed transient corneal edema after intravitreal injection of ocriplasmin.
    Zhang TY; Vachon-Joannette É; Proulx S; Légaré ME; Bourgault S
    Can J Ophthalmol; 2018 Apr; 53(2):e77-e79. PubMed ID: 29631850
    [No Abstract]   [Full Text] [Related]  

  • 2. Lamellar macular hole after intravitreal ocriplasmin injection.
    Chod RB; Goodrich C; Saxena S; Akduman L
    BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25576512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection.
    Quezada Ruiz C; Pieramici DJ; Nasir M; Rabena M; Avery RL
    Retin Cases Brief Rep; 2015; 9(2):145-8. PubMed ID: 25462129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography.
    Itoh Y; Kaiser PK; Singh RP; Srivastava SK; Ehlers JP
    Ophthalmology; 2014 Dec; 121(12):2506-2507.e2. PubMed ID: 25208855
    [No Abstract]   [Full Text] [Related]  

  • 5. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter S; Mennel S
    Acta Ophthalmol; 2018 May; 96(3):e409-e411. PubMed ID: 28771974
    [No Abstract]   [Full Text] [Related]  

  • 6. Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin.
    Barteselli G; Carini E; Invernizzi A; Ratiglia R; Viola F
    Acta Ophthalmol; 2016 Mar; 94(2):e160-2. PubMed ID: 26010219
    [No Abstract]   [Full Text] [Related]  

  • 7. [Unclear retinopathy after intravitreal injection of ocriplasmin].
    Abraham S; Wand K; Stumpfe S; Feucht N; Lohmann CP; Maier M
    Ophthalmologe; 2016 Feb; 113(2):156-9. PubMed ID: 26205745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient vision loss after ocriplasmin injection.
    Reiss B; Smithen L; Mansour S
    Retina; 2015 Jun; 35(6):1107-10. PubMed ID: 25901839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter-Reichart S; Mennel S
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute vision loss after ocriplasmin use.
    Reiss B; Smithen L; Mansour S
    Retin Cases Brief Rep; 2015; 9(2):168-9. PubMed ID: 25741635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin.
    Moisseiev J; Moroz I; Katz G
    JAMA Ophthalmol; 2014 Jun; 132(6):709-13. PubMed ID: 24723009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.
    Warrow DJ; Lai MM; Patel A; Raevis J; Berinstein DM
    Am J Ophthalmol; 2015 Jan; 159(1):20-30.e1. PubMed ID: 25220823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou?
    Kim JE
    JAMA Ophthalmol; 2014 Apr; 132(4):379-80. PubMed ID: 24577332
    [No Abstract]   [Full Text] [Related]  

  • 15. LONGITUDINAL MICROPERIMETRY EVALUATION AFTER INTRAVITREAL OCRIPLASMIN INJECTION FOR VITREOMACULAR TRACTION.
    Cacciamani A; Gelso A; Simonett JM; Ripandelli G; Pileri M; Stirpe M; Scarinci F
    Retina; 2017 Oct; 37(10):1832-1838. PubMed ID: 28033236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2014 Apr; 132(4):487-90. PubMed ID: 24577286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
    Luttrull JK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology.
    Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P
    Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.